Novotech and ETI Ally to Harness Indian Clinical Research Opportunities
Joint venture offers clients 92 trial sites in the country.!--h2>
Australia-based CRO, Novotech, and Indian CRO, ETI Klinical, are teaming up to help meet the growing international demand for clinical research in India.
The joint venture aims to cover a wide range of therapeutic areas including oncology, respiratory disorders, infectious diseases, psychiatry, metabolic disorders, devices, and vaccines. The firms will also offer flexible data management capabilities including Oracle Clinical and SAS as well as Novotech’s Clintrial.
Novotech’s Asian services were launched in 2007. This collaboration helps exploit what Novotech CEO, Alek Safarian, calls huge opportunities in the growing Indian clinical research sector. “We approached Novotech because of its proven reputation in the region, its focus on Australasia, and its global development reach and client network,” adds Karle Group CEO, Mahendra Karle.
By taking advantage of ETI’s extensive reach across India, the partners say that clients will have access to 92 trial-ready sites with proven recruitment capabilities and compliance, equating to over 5 million patients, 13,000 beds, and 760 investigators with a cumulative experience of 5,000 years.